FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome
The U.S. Food and Drug Administration approved Ruzurgi (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 to less than 17 years of age. This is the first FDA approval of a treatment specifically for pediatric patients with LEMS.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
More News: Children | Food and Drug Administration (FDA) | Myasthenia Gravis | Pediatrics | Pharmaceuticals